Combining Anti-ERBB3 Antibodies Specific for Domain I and Domain III Enhances the Anti-Tumor Activity over the Individual Monoclonal Antibodies

• Jimson W. D’Souza,

  Affiliation Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯
• Smitha Reddy ,

  Contributed equally to this work with: Smitha Reddy, Lisa E. Goldsmith

  Affiliation Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯
• Lisa E. Goldsmith ,

  Contributed equally to this work with: Smitha Reddy, Lisa E. Goldsmith

  Affiliation Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯
• Irina Shchaveleva,

  Affiliation Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯
• James D. Marks,

  Affiliation Department of Anesthesia and Pharmaceutical Chemistry, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Samuel Litwin,

  Affiliation Biostatistics and Bioinformatics Facility, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯
• Matthew K. Robinson

  * E-mail: matthew.robinson@fccc.edu

  Affiliation Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, PA, United States of America

  ⨯